Impact of immunosenescence and inflammaging on the effects of immune checkpoint inhibitors  

作　　者：Chuandong Hou Zining Wang Xuechun Lu 

机构地区：[1]Medical School of Chinese PLA,Beijing 100853,China [2]Department of Hematology,The Second Medical Center&National Clinical Research Center for Geriatric Diseases,Chinese PLA General Hospital,Beijing 100853,China

出　　处：《Cancer Pathogenesis and Therapy》2024年第1期24-30,共7页癌症发生与治疗（英文）

基　　金：This work was supported by the National Key Research and Development Program of China(No.2020YFC2002706);the Key Military Health Project(No.23BJZ25).

摘　　要：Immune checkpoint inhibitors(ICIs)are employed in immunotherapeutic applications for patients with weakened immune systems and can improve the ability of T cells to kill cancer cells.Although ICIs can potentially treat different types of cancers in various groups of patients,their effectiveness may differ among older individuals.The reason ICIs are less effective in older adults is not yet clearly understood,but age-related changes in the immune system,such as immunosenescence and inflammation,may play a role.Therefore,this review focuses on recent advances in understanding the effects of immunosenescence and inflammation on the efficacy of ICIs.

关 键 词：IMMUNOSENESCENCE INFLAMMAGING Immune checkpoint inhibitor 

分 类 号：R392[医药卫生—免疫学] R73[医药卫生—基础医学]